Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
Immune checkpoint inhibitors (ICIs) are approved for the treatment of a variety of cancer
types. The doses of these drugs, though approved by the Food and Drug Administration …
types. The doses of these drugs, though approved by the Food and Drug Administration …
Immune-related adverse events of immune checkpoint inhibitors
M Ramos-Casals, A Sisó-Almirall - Annals of Internal Medicine, 2024 - acpjournals.org
Immune-related adverse events (irAEs) are toxicities that arise after the administration of
monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) …
monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) …
Cancer nanovaccines: nanomaterials and clinical perspectives
Cancer nanovaccines represent a promising frontier in cancer immunotherapy, utilizing
nanotechnology to augment traditional vaccine efficacy. This review comprehensively …
nanotechnology to augment traditional vaccine efficacy. This review comprehensively …
Cancer immunotherapy and its facilitation by nanomedicine
Cancer immunotherapy has sparked a wave of cancer research, driven by recent successful
proof-of-concept clinical trials. However, barriers are emerging during its rapid development …
proof-of-concept clinical trials. However, barriers are emerging during its rapid development …
Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
Immune checkpoint inhibitors (ICI) have become integral to treatment of non-small cell lung
cancer (NSCLC). However, reliable biomarkers predictive of immunotherapy efficacy are …
cancer (NSCLC). However, reliable biomarkers predictive of immunotherapy efficacy are …
Selecting immune checkpoint inhibitor side effects for real-time monitoring in routine cancer care: a modified Delphi study
PURPOSE Electronic patient-reported outcome (ePRO) symptom monitoring may support
the safe delivery of immune checkpoint inhibitors (ICI). There is no consensus on which side …
the safe delivery of immune checkpoint inhibitors (ICI). There is no consensus on which side …
Co-design of an electronic patient-reported outcome symptom monitoring system for immunotherapy toxicities
Background Utilising electronic patient-reported outcomes (ePRO) to monitor symptoms can
improve patient outcomes. However, ePRO systems are typically not co-designed with end …
improve patient outcomes. However, ePRO systems are typically not co-designed with end …
Antibody-drug conjugates (ADCs): a novel therapy for triple-negative breast cancer (TNBC)
1Chitkara College of Pharmacy, Chitkara University, Rajpura, Chandigarh, India; 2Centre of
Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab …
Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab …
Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy
Y Zhou, J Zhou, X Hao, H Shi, X Li, A Wang… - Breast Cancer Research …, 2023 - Springer
Purpose Breast cancer has become the leading cause of cancer mortality in women.
Although immune checkpoint inhibitors targeting programmed death-1 (PD-1) are promising …
Although immune checkpoint inhibitors targeting programmed death-1 (PD-1) are promising …
Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta‐Analysis of Observational Studies and Randomized Controlled Trials
A Sharma, G Alexander, JH Chu… - Journal of the …, 2024 - Am Heart Assoc
Background Immune checkpoint inhibitors (ICIs) have uncommon associations with
cardiotoxicity, yet these cardiotoxic effects are associated with high mortality. An accurate …
cardiotoxicity, yet these cardiotoxic effects are associated with high mortality. An accurate …